Role of inflammation and infection in vascular disease

Acta Chirurgica Belgica

Volumn 105, Issue 6, 2005, Pages 567-579

  Corrado, E ^a   Novo, S ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atherosclerosis; C reactive protein; Chlamydia pneumoniae; Cytomegalic virus; Homocysteine; Inflammatoin

Indexed keywords

EID: 30544438907     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: 10.1080/00015458.2005.11679782     Document Type: Review

References (44)

1. PEARSON T., MENSAH G., ALEXANDER R. W., ANDERSON J. L., CANNON III R. O., CRIQUI M., FADL Y., FORTMANN S., HONG Y., MYERS G. L., RIFAI N., SMITH S., TAUBERT K., TRACY R., VINICOR F. Markers of Inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003, 107 : 499-511.
2. DANESH J., WHINCUP P., WALKER M. et al. Low grade inflammation and coronary heart disease : prospective study and updated meta-analyses. BMJ, 2000, 321 : 199-204.
3. RIDKER P. M., CUSHMAN M., TAMPFER J. S., RUSSELL P. T., HENNEKENS C. Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. N Engl J Med, 1997, 336 : 973-9.
4. RIDKER P. M., GLYNN J. G., HENNEKENS C. H. C-reactive protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction. Circulation, 1998, 97 : 2007-11.
5. RIDKER P. M., BURING J. E., SHIH J., MATIAS M., HENNEKENS C. H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation, 1998, 98 : 731-3.
6. BREVETTI G., PISCIONE F., SILVESTRO A., GALASSO G., DI DONATO A., OLIVA G., SCOPACASA F., CHIARIELLO M. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost, 2003, 89 : 1058-63.
7. VAINAS T., LUBBERS T., STASSEN F. R., HERNGREEN S. B., VAN DIEIJEN-VISSER M. P., BRUGGEMAN C. A., KITSLAAR P. J., SCHURINK G. W. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurismal tissue. Circulation, 2003, 107 : 1103-5.
8. NOVO S., BASILI S., TANTILLO R., FALCO A., DAVI V., NOVO G., CORRADO E., DAVI G. Soluble CD40L and cardiovascular risk in asymptomatic carotid plaque. Stroke, 2005, 36 : 673-5.
9. MARESCA G., DI BLASIO A., MARCHIOLI R., DI MINNO G. Measuring plasma fibrinogen to predict stroke and myocardial infarction : an update. Arterioscler Thromb Vasc Biol, 1999, 19 : 1368-77.
10. ABRIGNANI M. G., NOVO G., DI GIROLAMO A., CARUSO R., TANTILLO R., BRASCHI A., BRASCHI G. B., STRANO A., NOVO S. Increased plasmatic levels of fibrinogen in acute and chronic ischemic coronary syndromes. Cardiologia, 1999, 44 : 1047-52.
11. COPPOLA G., RIZZO M., ABRIGNANI M. G., CORRADO E., DI GIROLAMO A., BRASCHI G. B., NOVO S. Fibrinogen as predictor of mortality after acute myocardial infarction : a 42-months follow-up study. It Heart J, 2005, 6 : 315-22.
12. COPPOLA G., CORRADO E., MURATORI I., TANTILLO R., VITALE G., LO COCO L., NOVO S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol, 2005, e-publication.
13. RIDKER P. M., RIFAI N., PFEFFER M. A., SACKS F. M., MOYE L. A., GOLDMAN S., FLAKER G. C., BRAUNWALD E. Inflammation, Pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998, 98 : 839-44.
14. ALBERT M. A., DANIELSON E., RIFAI N., RIDKER P. M., for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels : the Pravastatin Inflammation/CRP Evaluation (PRINCE) : a randomized trial and cohort study. JAMA, 2001, 286 : 64-70.
15. RIDKER P. M., RIFAI N., CLEARFIELD M., DOWNS J. R., WEIS S. E., MILES J. S., GOTTO A. M. Jr, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med, 2001, 344 : 1959-65.
16. KINLAY S., SCHWARTZ G., OLSSON A. G., RIFAI N., LESLIE S., SASIELA W., SZAREK M., LIBBY P., GANZ P., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute CoronarySyndromes in the MIRACL Study. Circulation, 2003, 108 : 1560-6.
17. NISSEN S., TUZCU E. M., SCHOENHAGEN, BROWN G., GANZ P., VOGEL R. A., CROWE T., HOWARD G., COOPER C., BRODIE B., GRINES C. L., DEMARIA A., for the REVERSAL Investigators. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA, 2004, 291 : 1071-80.
18. RIDKER P. M., MORROW D., ROSE L., RIFAI N., CANNON C. P., BRAUNWALD E. Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol < 70 mg/dl and C-Reactive Protein < 2 mg/l. An Analysis of the PROVE-IT TIMI-22 Trial. J Am Coll Cardiol, 2005, 45 : 1644-8.
19. DE LEMOS J. A., BLAZING M. A., WIVIOTT S., LEWIS E., FOX K. A., WHITE C., ROULEAU J., PEDERSEN T., GARDNER L., MUKHERJEE R., RAMSEY K., PALMISANO J., BILHEIMER D., PFEFFER M., CALIFF R., BRAUNWALD E., for the A to Z Investigators. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients with Acute Coronary Syndromes Phase Z of the A to Z Trial. JAMA, 2004, 292 : 1307-16.
20. JIALAL I., STEIN D., BALIS D., GRUNDY S. M., ADAMS-HUET B., DEVARAJ S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 2001, 103 : 1933-5.
21. HORNE B. D., MUHLESTEIN J. B., CARLQUIST J. F., BAIR T. L., MADSEN T. E., HART N. I., ANDERSON J. L. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol, 2000, 36 : 1774-80.
22. DE MAAT M. P. M., KNIPSCHEER H. C., KASTELEIN J. J. P., KLUFT C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidemia. Thromb Haemost, 1997, 77 : 75-9.
23. CORTELLARO M., COFRANCESCO E., BOSCHETTI C., CORTELLARO F., MANCINI M., MARIANI M., PAOLETTI R., on behalf of the FACT study centers. Effects of fluvastatin and Bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidemia (FACT study). Thromb Haemost, 2000, 83 : 549-53.
24. HEISS G., SHARRETT A. R., BARNES R., CHAMBLESS L. E., SZKLO M., ALZOLA C. Carotid atherosclerosis measured by B-mode ultrasound in populations : associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol, 1991, 134 : 250-6.
25. ZHOU Y. F., LEON M. B., WACLAWIW M. A., POPMA J. J., YU Z. X., FINKEL T., EPSTEIN S. E. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med, 1996, 335 : 624-30.
26. EVERETT J. P., HERSHBERGER R. E., NORMAN D. J., CHOU S., RATKOVEC R. M., COBANOGLU A., OTT G. Y., HOSENPUD J. D. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant, 1992, 11 : S133-S137.
27. BIASUCCI L. M., LIUZZO G., CERVO A., PETRUCCA A., PIRO M., ANGIOLILLO D. J., CREA F., CASSONE A., MASERI A. Antibody Response to Chlamydial Heat Shock Protein 60 Is Strongly Associated With Acute Coronary Syndromes. Circulation, 2003, 107 : 3015-17.
28. HUITTINEN T., LEINONEN M., TEKANEN L., MÄNTTÄRI M., VIRKKUNEN H., PITKANEN T., WAHLSTRÖM E., PALOSUO T., MANNINEN V., SAIKKU P. Autoimmunity to Human Heat Shock Protein 60, Chlamydia pneumoniae Infection, and Inflammation in Predicting Coronary Risk. Arterioscler Thromb Vasc Biol, 2002, 22 : 431-7.
29. WICK G., PERCHINKA H., XU Q. Autoimmunity and atherosclerosis. Am Heart J, 1999, 138 : 444-9.
30. RIDKER P. M., DANESH J., YOUNGMAN L., COLLINS R., STAMPFER M. J., PETO R., HENNEKENS C. H. A Prospective Study of Helicobacter pylori Seropositivity and the Risk for Future Myocardial Infarction among Socioeconomically Similar U.S. Men. Ann Intern Med, 2001, 135 : 184-8.
31. ACETI A., ARE R., SABINO G., FENU L., PASQUAZZI C., QUARANTA G., ZECHINI B., TERROSU P. Helicobacter pylori active infection in patients with acute coronary heart disease. J Infect, 2004, 49 : 8-12.
32. HARA K., MORITA Y., KAMIHATA H., IWASAKA T., TAKAHASHI H. Evidence for infection with Helicobacter pylori in patients with acute myocardial infarction. Clin Chim Acta, 2001, 313 : 87-94.
33. SAIKKU P., LEINONEN M., TEKANEN L., LINNANMAKI E., EKMAN M. R., MANNINEN V., MÄNTTÄRI M., FRICK M. H., HUTTUNEN J. K. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med, 1992, 116 : 273-8.
34. TARNACKA B., GROMADZKA G., CZLONKOWSKA A. Increased Circulating Immune Complexes in Acute Stroke : The Triggering Role of Chlamydia pneumoniae and Cytomegalovirus. Stroke, 2002, 33 : 936-40.
35. JOHNSON S. P., OVERVAD K., OSTERGAARD L., TJONNELAND A., HUSTED S. E., SORENSEN H. T. Chlamydia pneumoniae seropositivity and risk of ischemic stroke : a nested case-control study. Eur J Epidemiol, 2005, 20 : 59-65.
36. CREMONINI F., GABRIELLI M., GASBARRINI G., POLA P., GASBARRINI A. The relationship between chronic H. pylori infection, CagA seropositivity and stroke : meta-analysis. Atherosclerosis, 2004, 173 : 253-9.
37. ZHU J., QUYYUMI A. A., NORMAN J. E., CSAKO G. A., SHEARER G. M., GRAYSTON J. T., EPSTEIN S. E. Total pathogen burden contributes incrementally to coronary artery disease risk and to C-reactive protein levels. Circulation, 1998, 98 (suppl. I) : I-142. Abstract.
38. CORRADO E., TANTILLO R., MURATORI I., EVOLA G., VITALE G., RIZZO M., MANSUETO S., STRANO A., NOVO S. Infection and inflammation influence the outcome of patients with asymptomatic carotid lesions. Int Angiol, 2004, 23 (Suppl. 1 to issue no 1), pp. 168. Abstract.
39. MURATORI I., VITALE G., EVOLA S., EVOLA G., TANTILLO R., MOCCIARO C., NOTO D., DI GIOVANNI S., DI SIMONE E., GIGLIA S., MANSUETO S., NOVO S. Infection from Helicobacter Pylori, Chlamydia Pneumoniae, Cytomegalovirus, levels of C-reactive protein and fibrinogen in patients with acute and chronic coronary ischemia in comparison with control subjects. Min Cardioangiol, 2001, 49 (Suppl. 1/6) : 192-4.
40. ANDERSON J. L., MUHLESTEIN J. B., CARLQUIST J., ALLEN A., TREHAN S., NIELSON C. et al. Randomized secondary prevention trial of Azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection : The Azithromycin in Coronary Artery Disease : Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation, 1999, 99 : 1540-7.
41. GRAYSTON J. T. Secondary prevention antibiotic treatment trials for coronary artery disease. Circulation, 2000, 102 : 1742-3.
42. GURFINKEL E., BOZOVICH G., DAROCA A., BECK E., MAUTNER B. Randomised trial of Roxithromycin in non-Q-wave coronary syndromes : ROXIS Pilot Study. ROXIS Study Group. Lancet, 1997, 350 : 404-7.
43. SINISALO J., MATTILA K., VALTONEN V., ANTTONEN O., JUVONEN J., MELIN J. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation, 2002, 105 : 1555-60.
44. NEUMANN F., KASTRATI A., MIETHKE T., POOATSA-MURRAY G., MEHILLI J., VALINA C. Treatment of Chlamydia pneumoniae infection with Roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3) : a randomised, double-blind, placebo-controlled trial. Lancet, 2001, 357 : 2085-9.